DEFA14A: Pacira BioSciences Faces Director Nomination Challenge from DOMA Perpetual

Pacira BioSciences confirms receipt of director nominations from DOMA Perpetual Capital Management and states that no shareholder action is required at this time.

Summary

• Pacira BioSciences has received nominations for three director candidates from DOMA Perpetual Capital Management for the 2025 Annual Meeting of Stockholders.
• Pacira's Board, through its Nominating, Governance and Sustainability Committee, will evaluate the proposed candidates.
• The Board will present its formal recommendation regarding director nominees in the company's definitive proxy statement.
• Pacira emphasizes that shareholders are not required to take any action at this time.
• Pacira highlights its '5x30' plan aimed at enhancing shareholder value.
• The company is making progress across its commercial portfolio and meeting guidance, as evidenced by strong Q4 2024 financial results.
• Pacira has made important acquisitions, such as the recent GQ Bio transaction, toward long-term value creation.
• Pacira has treated more than 16 million patients with EXPAREL as of February and expects to help manage postsurgical pain in more than 18 million patients by year end.
• Pacira is executing against its refreshed mission alongside its revised guiding principles and core values.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company faces a challenge from a shareholder activist, it emphasizes its commitment to enhancing shareholder value and highlights recent achievements. The presence of forward-looking statements and risk factors tempers the overall optimism.

Positives

• Pacira is taking decisive action to enhance shareholder value through its '5x30' plan.
• The company reported strong Q4 2024 financial results.
• Pacira is making progress across its commercial portfolio and meeting guidance.
• The GQ Bio acquisition is expected to contribute to long-term value creation.
• EXPAREL has been used to treat a significant number of patients, with further growth expected.

Negatives

• DOMA's nomination of director candidates suggests potential disagreement with Pacira's current strategy or board composition.
• The company acknowledges that DOMA's announcement contains purposeful misstatements.

Risks

• The company faces risks related to the failure to realize the anticipated benefits and synergies from the acquisition of GQ Bio.
• Risks are associated with acquisitions, such as the risk that the acquired businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur.
• Pacira's manufacturing and supply chain, global and U.S. economic conditions (including inflation and rising interest rates), and Pacira's business, including Pacira's revenues, financial condition, cash flow and results of operations are risks.
• The success of Pacira's sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera is a risk.
• The rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera is a risk.
• The size and growth of the potential markets for EXPAREL, ZILRETTA and iovera and Pacira's ability to serve those markets is a risk.
• Pacira's plans to expand the use of EXPAREL, ZILRETTA and iovera to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA and iovera is a risk.
• The commercial success of EXPAREL, ZILRETTA and iovera is a risk.
• The related timing and success of U.S. Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s is a risk.
• The related timing and success of European Medicines Agency Marketing Authorization Applications is a risk.
• Pacira's plans to evaluate, develop and pursue additional product candidates utilizing Pacira's proprietary multivesicular liposome (pMVL) drug delivery technology is a risk.
• The approval of the commercialization of Pacira's products in other jurisdictions is a risk.
• Clinical trials in support of an existing or potential pMVL-based product is a risk.
• Pacira's commercialization and marketing capabilities is a risk.
• Pacira's ability to successfully complete capital projects is a risk.
• The outcome of any litigation is a risk.
• The recoverability of Pacira's deferred tax assets is a risk.
• Assumptions associated with contingent consideration payments is a risk.
• Assumptions used for estimated future cash flows associated with determining the fair value of the Company is a risk.
• The anticipated funding or benefits of Pacira's share repurchase program is a risk.

Future Outlook

Pacira is confident that it is well positioned to accelerate growth and continue executing its long-term strategy, including the '5x30' plan.

Management Comments

• Pacira's Board and management team are taking decisive action to enhance shareholder value.
• We recently completed a comprehensive portfolio review and defined our 5x30 plan as the best plan to deliver shareholder value.
• It is business as usual at Pacira as we continue to advance our important mission to deliver innovative, non-opioid pain therapies to transform the lives of patients.
• Thanks to your hard work, we are already making strong strides against our 5x30 strategy.
• I'm confident that we have the right team and the right strategy in place to build on the momentum underway and drive future growth for many years to come.

Industry Context

The announcement reflects increasing shareholder activism in the pharmaceutical industry, with investors seeking to influence company strategy and board composition.

Comparison to Industry Standards

• It is difficult to compare Pacira's situation to industry standards without knowing the specific details of DOMA's concerns and the proposed director candidates.
• Shareholder activism is a common occurrence in the pharmaceutical industry, with examples such as Carl Icahn's involvement with Biogen and ValueAct Capital's engagement with multiple healthcare companies.
• The success of Pacira's '5x30' plan will be a key factor in determining whether the company can maintain its independence and deliver value to shareholders.

Stakeholder Impact

• Shareholders will be impacted by the outcome of the director election and the company's strategic direction.
• Employees are assured that DOMA's announcement has no impact on their day-to-day responsibilities or the company's priorities.
• Patients are expected to benefit from Pacira's continued focus on delivering innovative, non-opioid pain therapies.

Next Steps

• The Nominating, Governance and Sustainability Committee of Pacira's Board will evaluate DOMA's proposed director candidates.
• Pacira will file a definitive proxy statement with the SEC.
• Pacira will mail the proxy statement to all shareholders eligible to vote at the 2025 Annual Meeting of Stockholders.
• Shareholders will vote on the election of directors at the 2025 Annual Meeting.

Key Dates

Keywords

Pacira BioSciences, DOMA Perpetual, Director Nominations, Proxy Statement, Shareholder Value, EXPAREL, ZILRETTA, iovera, 5x30 plan, GQ Bio, Annual Meeting, Board of Directors